The latest on several drugs being tested for the treatment of COVID-19:
- Eli Lilly's rheumatoid arthritis drug baricitinib, sold under the brand name Olumiant, prevented 1 death for every 6 patients on a ventilator in a phase 3 clinical trial.
- The FDA revised its emergency use authorization for Regeneron's COVID-19 antibody cocktail of casirivimab and imdevimab, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
- Bamlanivimab or casirivimab-imdevimab, two monoclonal antibodies, were effective in preventing hospitalization among high-risk patients with COVID-19 when administered separately in a real-world study.
- Gilead's remdesivir may be associated with longer hospital stays for COVID-19 patients, even after they have recovered, so that they can finish the treatment course, a study suggested.
- The antibiotic azithromycin didn't reduce the risk of hospitalization, respiratory failure or death in COVID-19 patients in a clinical trial.